Who is sponsoring NCT05928962?

NCT05928962 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT05928962?

Interventions in NCT05928962: Recombinant Human Adenovirus Type 5 Injection.

What condition does NCT05928962 study?

NCT05928962 studies Malignant Melanomas.

Is NCT05928962 still recruiting?

NCT05928962 is currently status unknown. Last updated 10 July 2023.

Last reviewed 2023-07-10 · How we verify

NCT05928962

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Status unknown Phase 1 Last updated 10 July 2023

What this trial tests

Phase 1 trial testing Recombinant Human Adenovirus Type 5 Injection in Malignant Melanomas in 10 participants. Status unknown.

Timeline

27 October 2022

Primary endpoint
1 August 2023

31 October 2024

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	27 October 2022
Primary completion	1 August 2023
Estimated completion	31 October 2024
Sites	1 location across China

Drugs / interventions tested

Recombinant Human Adenovirus Type 5 Injection — full drug profile →

Conditions studied

Malignant Melanomas — all drugs for Malignant Melanomas →

Sponsor

Fujian Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Malignant Melanomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is provide new treatment for patients with advanced melanoma who have failed previous immunotherapy. The main questions it aims to answer are: * Efficacy of PD1 monoclonal antibody combined with recombinant human adenovirus type 5 injection in patients with advanced malignant melanoma. * Safety of PD1 monoclonal antibody combined with recombinant human adenovirus type 5 injection in patients with advanced malignant melanoma.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint inhibitors in metastatic melanoma therapy (Review).
Shah V, Panchal V, Shah A, Vyas B, et al · · 2024 · cited 19× · PMID 38410760 · DOI 10.3892/mi.2024.137
Recent advances in oncolytic virus combined immunotherapy in tumor treatment.
Zhou X, Hu S, Wang X. · · 2025 · cited 4× · PMID 40821119 · DOI 10.1016/j.gendis.2025.101599
Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms.
Cheng C, Wang Q, Zhang S. · · 2025 · cited 2× · PMID 40698086 · DOI 10.3389/fimmu.2025.1610858
Enhancing antitumor immunity through oncolytic viruses: advances in genetic engineering.
Zubair A, Lazarou L, Alkahtani AM, Shahani MY, et al · · 2026 · PMID 41811580 · DOI 10.1007/s12672-026-04792-w

Verify or expand the search:

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05928962 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 10 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05928962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing